Inhaled short acting beta2-agonist use in chronic asthma: regular versus as needed treatment

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 1, 2003, Pages

  Walters, E Haydn ^a   Walters, Julia AE ^b   Gibson, Peter G ^c   Jones, Paul ^d  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; HUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG ADMINISTRATION SCHEDULE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 18844476198     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001285     Document Type: Article

References (148)

1. Aldridge RE, Hancox RJ, Robin Taylor D, Cowan JO, Winn MC, Frampton CM, et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. American Journal of Respiratory and Critical Care Medicine 2000;161(5):1459-64.
2. Hancox RJ, Aldridge RE, Cowan JO, et al. Tolerance to beta-agonists during acute bronchoconstriction. European Respiratory Journal 1999;14:283-7.
3. Aldridge RE, Hancox RJ, Robin Taylor D, Cowan JO, Winn MC, Frampton CM, et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. American Journal of Respiratory and Critical Care Medicine 2000;161(5):1459-64.
4. Hancox RJ, Aldridge RE, Cowan JO, et al. Tolerance to beta-agonists during acute bronchoconstriction. European Respiratory Journal 1999;14:283-7.
5. Apter AJ, Reisine ST, Willard A, Clive J, Wells M, Metersky M, et al. The effect of inhaled albuterol in moderate to severe asthma. Journal of Allergy and Clinical Immunology 1996;98:295-301.
6. Bennati D, Piacentini G, Peroni DG, Sette L, Testi R, Boner AL. Changes in bronchial reactivity in asthmatic children after treatment with beclomethasone alone or in combination with salbutamol. Journal of Asthma 1989;26:359-64.
7. Bensch G, Lapidus R, Levine B, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Annals of Allergy, Asthma, & Immunology 2001;86:19-27.
8. Della Cioppa G, Kiseley P, Matos D, Yegen I, Townley RG. QID Albuterol worsens peak flow variability in asthma whereas BID Formoterol does not. Annals of Allergy Asthma and Immunology 1998;80:88.
9. Beswick KB, Pover GM, Sampson S. Long-term regularly inhaled salbutamol. Current Medical Research and Opinion 1986;10:228-34.
10. Chapman KR, Kesten S, Szalai JP. Regular vs as-needed inhaled salbutamol in asthma control. Lancet 1994;343:1379-82.
11. Chavasse R, Bastian-Lee Y, Richter H, Hilliard T, Seddon PA. Inhaled salbutamol for wheezy infants: a randomised controlled trial. Archives of Disease in Childhood 2000;82:370-5.
12. Cloosterman SG, Bijl-Hofland ID, van Herwaarden CL, et al. A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients. Chest 2001;119:1306-15.
13. Cloosterman SG, Schermer TR, Bijl-Hofland ID, Van Der Heide S, Brunekreef B, Van Den Elshout FJ, et al. Effects of house dust mite avoidance measures on Der p 1 concentrations and clinical condition of mild adult house dust mite-allergic asthmatic patients, using no inhaled steroids. Clinical and Experimental Allergy 1999;29(10):1336-46.
14. van Schayck CP, Cloosterman SG, Bijl-Hofland ID, van den Hoogen H, Folgering HT, van Weel C. Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists. Respiratory Medicine 2002;96(3):155-62.
15. Cockcroft DW, McParland CP, Britto SA, Swystun V, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993;342:833-7.
16. Cockcroft DW, Swystun VA, Bhagat R. Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. American Journal of Respiratory and Critical Care Medicine 1995;52:1485-9.
17. Cockcroft DW, Swystun VA, Bhagat R. Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. American Journal of Respiratory and Critical Care Medicine 1995;52:1485-9.
18. Cockcroft DW, O'Byrne PM, Swystun VA, Bhagat R. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. Journal Allergy and Clinical Immunology 1995;96:44-9.
19. Swystun VA, Bhagat MB, O'Byrne PM, Cockroft DW. Regular inhaled salbutamol increases allergen induced late asthmatic responsiveness [abstract]. Journal Allergy & Clinical Immunology 1994;9:260s.
20. D'Alonzo GE, Nathan RA, Henchowicz S, Morris RJ, Ratner P, Rennard SJ. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994;271:1412-6.
21. D’Alonzo GE. Efficacy of inhaled salmeterol in the treatment of asthma. European Respiratory Review 1995;5:128-32.
22. Pearlman D. Long-acting beta 2-agonist salmeterol compared with albuterol in maintenance asthma therapy. Ann Allergy Asthma Immunol 1995;75:180-4.
23. De Jong JW, Van der Mark TW, Koeter GH. Rebound airway obstruction and responsiveness after cessation of terbutaline: Effects of budesonide. American Journal of Respiratory and Critical Care Medicine 1996;153:70-5.
24. De Jong JW, Van der Mark TW, Koeter GH. Rebound airway obstruction and responsiveness after cessation of terbutaline: Effects of budesonide. American Journal of Respiratory and Critical Care Medicine 1996;153:70-5.
25. Dennis S, Sharp S, Vickers M, et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Lancet 2000;355:1657-79.
26. Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, et al. Comparison of Regularly Scheduled with As-Needed Use of Albuterol in Mild Asthma. New England Journal of Medicine 1996;335:841-7.
27. Ekstrom T, Ringdal N, Tukiainen P, Runnerstrom E, Soliman S. A three month comparison of formoterol with terbutaline via turbuhaler. A placebo controlled study. Annals of Allergy, Asthma and Immunology 1998;81:225-30.
28. Ekstrom T, Ringdal N, Sobradillo V, Runnerstrom E, Soliman S. Low-dose formoterol Turbuhaler(TM) (Oxis(TM)) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.). Respiratory Medicine 1998;92:1040-5.
29. FitzGerald J, Chapman K, Della Cioppa G, et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. Journal of Allergy & Clinical Immunology 1999;103:427-35.
30. Ganassini A, Rossi A. Short-term regular beta 2-adrenergic agonist treatment is safe in mild asthmatics taking low doses of inhaled steroids. Journal of Asthma 1997;34:61-6.
31. Gauvreau GM, Jordana M, Watson RM, Cockcroft DW, O'Byrne PM. Effect of regular inhaled albuterol on allergen induced late responses and sputum eosinophils in asthmatic subjects. American Journal of Respiratory and Critical Care Medicine 1997;156:1738-45.
32. Hancox R, Cowan J, Flannery E, et al. Randomised trial of an inhaled beta2 agonist, inhaled corticosteroid and their combination in the treatment of asthma. Thorax 1999;54:482-7.
33. Hancox RJ, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, Taylor DR. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respiratory Medicine 2000;94:767-71.
34. Hancox RJ, Stevens DA, Adcock IM, Barnes PJ, Taylor DR. Effects of inhaled beta agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma. Thorax 1999;54(6):488-92.
35. Hancox R, Cowan J, Flannery E, et al. Randomised trial of an inhaled beta2 agonist, inhaled corticosteroid and their combination in the treatment of asthma. Thorax 1999;54:482-7.
36. Hancox RJ, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, Taylor DR. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respiratory Medicine 2000;94:767-71.
37. Hancox RJ, Stevens DA, Adcock IM, Barnes PJ, Taylor DR. Effects of inhaled beta agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma. Thorax 1999;54(6):488-92.
38. Hancox RJ, Subbarao P, Kamada D, Watson R, Hargreave F, Inman MD. Beta2-agonist tolerance and exercise-induced bronchospasm. American Journal of Respiratory & Critical Care Medicine 2002;165(8):1068-70.
39. Inman M, O'Byrne P. The effect of regular inhaled salbutamol treatment for 1 week on exercise-induced bronchoconstriction. American Journal of Respiratory and Critical Care Medicine 1995;151:A40.
40. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. American Journal of Respiratory and Critical Care Medicine 1996;153:65-9.
41. Juniper EF, Johnston P, Borkhoff, C, Haukioja A. A multicentre comparison of salmeterol and salbutamol on asthma-specific quality of life [abstract]. Quality of Life Research 1994;3:83.
42. Juniper EJ, Johnston PR, Borkhoff CM, Guyatt GH, Boulet LP, Haukioja A. Quality of life in asthma clinical trials: a comparison of salmeterol and salbutamol. American Journal of Respiratory and Critical Care Medicine 1995;151:66-70.
43. Kemp J, Wolfe J, Grady J, et al. Salmeterol powder compared with albuterol aerosol as maintenance therapy for asthma in adolescent and adult patients. Clinical Therapeutics 1998;20:270-82.
44. Wolfe J, LaForce C, Chervinsky P, et al. Inhaled salmeterol powder compared with albuterol aerosol given regularly or as needed for asthma. Annals of Allergy, Asthma and Immunology 1995;74:52s.
45. Larsen G, Harper T, Laurence M, et al. Inhaled albuterol powder is safe and efficacious in the treatment of paediatric patients with mild asthma. ATS proceedings. 1998:A709.
46. Leblanc P, Knight A, Kreisman H, Borkhoff CM, Johnston PR. A placebo controlled crossover comparison of salmeterol and salbutamol in patients with asthma. American Journal of Respiratory and Critical Care Medicine 1996;154:324-8.
47. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. American Review of Respiratory Disease 1989;140:586-92.
48. Lipworth B, Tan S, Devlin M, Aiken T, Baker R, Hendrick D. Effects of treatment with formoterol on bronchoprotection against methacholine. American Journal of Medicine 1998;104:431-8.
49. Davies R, Trigg CJ, Wang N, Mannolitsas N, Macaulay A, Jhalli N, Hamilton S. Regular inhaled salbutamol may exacerbate bronchial inflammation in patients with mild asthma. Thorax 1993;48:1060.
50. Manolitsas ND, Wang J, Devalia JL, Trigg CJ, McAulay AE, Davies RJ. Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. American Journal of Respiratory & Critical Care Medicine 1995;151:1925-30.
51. Nelson H, Kemp J, Bieler S, Vaughan L, Hill M. Comparative efficacy and safety of albuterol sulfate spiros inhaler and albuterol metered-dose inhaler in asthma. Chest 1999;115:329-35.
52. O'Connor BJ, Aikman S, Barnes PJ. Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. New England Journal Of Medicine 1992;327:1204-8.
53. Patakas D, Maniki E, Tsara V, Daskalopoulou E. Intermittent and continous salbutamol rotacaps inhlation in asthmatic patients. Respiration 1988;54:174-8.
54. D’Alonzo GE. Efficacy of inhaled salmeterol in the treatment of asthma. European Respiratory Review 1995;5:128-132.
55. Pearlman DS. Long-acting beta 2-agonist salmeterol compared with albuterol in maintenance asthma therapy. Ann Allergy Asthma Immunol 1995;75:180-4.
56. Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. New England Journal Of Medicine 1992;327:1420-5.
57. Sears MR, Taylor Dr, Print CG, Lake DC, Li QQ, Flannery EM, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6.
58. Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, Lake DC, et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 1993;48:134-8.
59. Shepherd GL, Hetzel MR, Clark TJH. Regular versus symptomatic aerosol bronchodilator treatment of asthma. British Journal of Diseases of the Chest 1981;75:215-7.
60. Steffensen I, Faurschou P, Riska H, et al. Inhaled formoterol DP in the treatment of patients with ROAD. A 3mth, placebo-cont comparison of the efficacy and safety of formoterol and salbutamol. Allergy 1995;50:657-63.
61. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: Influence of beta2 adrenoceptor polymorphism. Thorax 2000;55:762-7.
62. Taylor DR, Town GI, Herbison GP, Boothman-Burrell D, FLannery EM, Hancox B, et al. Asthma control during long term treatment with regular inhaled salbutamol and salmeterol. Thorax 1998;53:744-52.
63. Tormey VJ, Faul J, Leonard C, Lennon A, Burke CM. A comparison of regular with intermittent bronchodilators in asthma patients on inhaled steroids. Irish Journal of Medical Science 1997;166:249-52.
64. Vathenen AS, Knox A, Higgins BG, Britton JR, Tattersfield AE. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988;1:554-8.
65. Wahedna I, Wong Cs, Wisniewski AFZ, Pavord ID, Tattersfield AE. Asthma control during and after cessation of regular beta2-agonist treatment. American Review of Respiratory Disease 1993;148:707-12.
66. Wilding PJ, Clark MM, Oborne J, Bennett JA, Tattersfield AE. Effect of regular terbutaline on the airway response to inhaled budesonide. Thorax 1996;51:989-92.
67. Wong CS, Waheda I, Pavord ID, Tattersfield AE. Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge. American Journal of Respiratory and Critical Care Medicine 1994;150:1268-73.
68. Wong CS, Waheda I, Pavord ID, Tattersfield AE. Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge. American Journal of Respiratory and Critical Care Medicine 1994;150:1268-73.
69. Zellweger JP, Clottu R, Crittin A, Dottrens A, Heinzer F, Stinghe R, Vodoz JM. Comparative study of the effects of regular or on-demand salbutamol inhalation in the treatment of asthma. Schweizerische medizinische Wochenschrift 1986;116:1260-3.
70. Adelroth E, Rosenhall L, Johansson SA, Linden M, Venge P. Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. The effects of antiasthmatic treatment with budesonide or terbutaline. American Review of Respiratory Disease 1990;142(1):91-99.
71. Beall GN, Steen Sn, Kuo J, Smith R. A three month study of the bronchodilator effects of aerosolized fenoterol and isoproterenol. Chest 1978;73:s996-7.
72. Bhatia SP, Davies H J. Evaluation of tolerance after continuous and prolonged oral administration of salbutamol to asthmatic patients. British Journal of Clinical Pharmacology 1975;2:463-6.
73. Boothman-Burrell D, Jones D, Herbison GP, Taylor DR. The effect of regular salbutamol on lung function and bronchial hyperresponsiveness in normal subjects and non-asthmatic atopic subjects with allergic rhinitis. Chest 1997;112:12-8.
74. Chapman KR, Smith DL, Rebuck AS. Hemodynamic effects of an inhaled beta-2 agonist. Clinical Pharmacology and Therapeutics 1984;35:762-7.
75. Cochrane GM. Regular versus intermittent inhaled bronchodilator therapy in the treatment of asthma. Research and Clinical Forums 1984;6:55-9.
76. Cockcroft DW, Swstun V, Bhagat R. Salmeterol and airway response to allergen. Canadian Respiratory Journal 1997;4:37-40.
77. de Jong JW, Koeter GH, van der Mark TW. Postma DS. Effects of cessation of terbutaline treatment on airway obstruction and responsiveness in patients with chronic obstructive pulmonary disease. Thorax 1996;51:684-8.
78. Evans DW, Salome CL, King GG, Rimmer SJ, Seale JP, Woolcock AJ. Effect of regular inhaled salbutamol on airway responsiveness and airway inflammation in rhinitic non-asthmatic subjects. Thorax 1997;52:136-42.
79. Fairfax A, Mcnabb W, Davies HJ, Spiro SG. Slow release oral salbutamol and aminophylline in nocturnal asthma: relation of overnight changes in lung function and plasma drug levels. Thorax 1980;35:526-30.
80. Felix R, Hedde JP, Zwicker HJ, et al. Mucociliary clearance during beta-adrenergic stimulation with Fenoterol. PRAX KLIN PNEUMOL 1978;32:777-82.
81. Gauvreau GM, Watson RM, Jordana M, et al. The effect of regular inhaled salbutamol on allergen induced airway responses and inflammatory cells in blood and induced sputum. American Journal of Respiratory and Critical Care Medicine 1995;151:A39.
82. Gibson J, Greenacre JK, Konig P, Connolly ME, Pride NB. Use of exercise challenge to investigate possible tolerance to beta adrenergic stimulation in asthma. British Journal of Diseases of the Chest 1978;72:199-206.
83. Hanley SP, Nunn AJ. Treatment of nocturnal asthma with fenoterol (Berotec). A comparison with salbutamol and placebo. Clinical Trials Journal 1979;16:34-6.
84. Harvey JE, Tattersfield A. Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax 1982;37:280-7.
85. Heino M. Regularly inhaled beta-agonists with steroids are not harmful in stable asthma. Journal of Allergy and Clinical Immunology 1994;93:80-4.
86. Ishihara K, Sakamoto H, Tomioka H, Hasegawa T, Okazaki M, Katakami N, et al. Use of beta-agonist inhalation concomitantly with regular BDP in patients with bronchial asthma-as required or on a regular basis. Japanese Journal of Thoracic Diseases 1992;30:808-14.
87. Kerribijn K, van essen Zandvliet EEM. Effect of long term treatment with inhaled corticosteroids and beta agonists on the bronchial responsiveness in children with asthma. Journal of Allergy and Clinical Immunology 1987;79:653-9.
88. Kraan J, Koeter GH, van den Mark TW, Sluiter HJ, de Vries K. Changes in bronchial hyperreactivity induced by four weeks treatment with anti asthma drugs in patients with allergic asthma. a comparison between budesonide and terbutaline. Journal of Allergy & Clinical Immunology 1985;76:628-36.
89. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. Journal of Allergy Clinical Immunology 1992;90(1):32-42.
90. Larsson K, Martinsson A, Hjemdahl P. Influence of beta -adrenergic receptor function during terbutaline treatment on allergen sensitivity and bronchodilator response to terbutaline in asthmatic subjects. Chest 1992;101:953-60.
91. Nelson HS, Raine D, Doner HC, Posey WC. Subsensitivity to the bronchodilator action of albuterol produced by chronic administration. American Review of Respiratory Disease 1977;116:871-8.
92. Peel ET, Gibson GJ. Effectsof long term inhaled salbutamol therapy on the provocation of asthma by histamine. American Review of Respatory Disease 1980;121:973-8.
93. Rachelefsky GS, Katz RM, Siegel SC. Oral albuterol in the treatment of childhood asthma. Pediatrics 1982;69:397-403.
94. Repscher LH, Anderson LH, Bush R, et al. Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest 1984;85:34-8.
95. Richter B, Bender R, Berger M. Effects of on-demand beta2-agonist inhalation in moderate-to-severe asthma. A randomized controlled trial. Journal of Internal Medicine 2000;247:657-66.
96. Richter B, Buselic K, Richter A, Berger M. Continous v on demand inhaled beta agonist on the basis of regular inhaled corticosteroids:a randomised controlled study. European Respiratory Journal 1995;8:159S.
97. Sears M, Taylor DR, Print CG, Lake DC, Herbison GP, Flannery EM. Increased inhaled bronchodilator versus increased inhaled corticosteroid in the control of moderate asthma. Chest 1992;102:1709-15.
98. Town GI, O'Donnell T V, Purdie G. Bronchial responsiveness during regular fenoterol therapy: four months prospective study. New Zealand Medical Journal 1991;104(904):3-5.
99. Trembath P, Greenacre JK, Anderson M, Dimmock S, Mansfield L, Wadsworth J, Green M. A comparison of four weeks treatment with fenoterol and terbutaline aerosols in adult asthmatics. Journal of Allergy and Clinical Immunology 1979;63:395-400.
100. van den Berg W, Leferink J, Fokkens JK, Kreukniet J, Maes RAA, Bruynzeel PLB. Clinical implications of drug-induced desensitization of the beta receptor after continuous oral use of terbutaline. Journal of Allergy and Clinical Immunology 1982;69:410-17.
101. van Schayck CP, Graafsma SJ, Visch MB, Dompeling E, van Weel C, van Herwaarden CLA. Increased bronchial hyperesponsiveness after inhaling salbutamol during one year is not caused by subsensitisation to salbutamol. Journal of Allergy and Clinical Immunology 1990;81:793-800.
102. van Schayck CP, Dompeling E, van Herwaarden CLA, Folgering H, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: Continuous or on demand? A randomised controlled study. British Medical Journal 1991;303:1426-31.
103. van Schayck CP, Folgering H, den Otter JJ, Tirimanna P, van Weel C. Does the continuous use of bronchodilators mask the progression of asthma or chronic bronchitis?. Family Practice 1992;9:397-404.
104. van Schayck CP, Rutten-v-Molken M, van Doorslaer EKA, Folgering H, van Weel C. Two-year bronchodilator treatment in patients with mild airflow obstruction; Contradictory effects on lung function and quality of life. Chest 1002;102:1384-91.
105. Van Schayck CP, Folgering H, den Otter JJ, et al. Does continuous use of bronchodilators disguise the progression of chronic non specific lung diseases. Tijdschrift voor Geneskunde 1994;50:787-94.
106. van Schayck CP, Dompeling E, van Herwaarden CL, et al. Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis: four-year follow-up RCT. British Journal Of General Practice 1995;445:239-44.
107. VanArsdel PP, Schaffrin RM, Rosenblatt J, Sprenkle AC, Altman LC. Evaluation of oral fenoterol in chronic asthmatic patients. Chest 1978;73:997-8.
108. Wong AG, O'Shaugnessy SA, Walker CM, Sears MR. Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics. European Respiratory Journal 1997;10:330-6.
109. Executive committee American Academy of Allergy and Clinical Immunology. Inhaled beta2 agonist in asthma. Journal of Allergy & Clinical Immunology 1993;91:1234-7.
110. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease and asthma. American Journal of Respiratory & Critical Care Medicine 1995;152:s77-s121.
111. Barrett T, Strom B. Inhaled beta adrenergic receptor agonists in asthma: more harm than good?. American Journal of Respiratory & Critical Care Medicine 1995;151:574.
112. Bosco L, Knapp D, Gerstman B, Graham C. Asthma drug therapy trends in the United states, 1972 to 1985. Journal of Allergy & Clinical Immunology 1987;80:398-401.
113. British Thoracic Society. Guidelines on the management of asthma. Thorax 1993;48:S1-24.
114. British Thoracic Society, NAtional Asthma Caompaign, Royal College of Pysicians. The British guidelines on Asthma Management 1995 review and position statement. Thorax 1997;52:S1.
115. Campbell A. Mortality from asthma and bronchodilator aerosols. Medical Journal of Australia 1976;1:386-91.
116. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand 1981-1983,ca case control study. Lancet 1989;1:917-22.
117. Crompton GK. Bronchodilator treatment in asthma. Regular treatment with beta agonists remains unevaluated. British Medical Journal 1993;306:1610-1.
118. Ernst P, Habbick B, Suissa S, Hemmelgarn B, Cockroft D, Buist AS. Is the association between inhaled beta-agonist use and life- threatening asthma because of confounding by severity?. American Review of Respiratory Disease 1993;148:75-9.
119. Fahy JV, Boushey H. Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma. Clinics in Chest Medicine 1995;16:715-33.
120. Fireman P. Beta2 agonists and their safety in the treatment of asthma. Allergy Proceedings 1995;16:235-9.
121. Fuller RW, Castle WM, Hall JR, Palmer JBD. Letter- authors reply- Bronchodilator treatment in asthma. BMJ 1993; Vol. 306:1611.
122. Gibson P, Henry D, Francis L, et al. Association between availability of non-prescription beta 2 agonist inhalers and undertreatment of asthma. BMJ 1993;306:1514-8.
123. Giuntini CG, Paggiaro PL. Present state of the controversy about regular inhaled beta-agonists in asthma [Review]. European Respiratory Journal 1995;8:673-8.
124. Haatela T, Jarvinen M, Kava T, et al. Comparison of a beta agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. New England Journal of Medicine 1991;315:388-92.
125. Jackson R, Sears M, Beaglehole R, Rea HH. International trends in asthma mortality: 1970 to 1985. Chest 1998;94:914-8.
126. Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds J, Gavaghan D, et al. Assessing the quality of reports of randomised control trials: is blinding really neccesary?. Controlled Clinical Trials 1996;17:1-12.
127. Jenkins M, Hurley S, Bowes G, McNeil JJ. Use of antiasthmatic drugs in Australia. Medical Journal of Australia 1990;153:323-8.
128. Juniper EF, Guyatt GH. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83.
129. Kiutert LM. Beta agonists in asthma-state of the art: a report on a Royal Society of Medicine seminar. Thorax 1992;47:568-9.
130. Koeter GH, Meurs H, Kauffman HF, de Monchy JGR, Sluiter HJ, de Vries K. Changes in the beta adrenergic system in bronchial asthma induced by terbutaline. Agents Actions 1983;13:s259-264.
131. Kuschner WG, Hankinson TC, Wong HH, Blanc PD. Nonprescription bronchodilator medication use in asthma. Chest 1997;112:987-93.
132. Lai CKW, Twentyman OP, Holgate ST. The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial hyperresponsiveness. American Review of Respiratory Disease 1989;140:917-23.
133. National Asthma Education Program Expert Panel Report, National Heart Lung and Blood Institute. Guidelines for the diagnosis and management of asthma. Journal of Allergy & Clinial Immunology 1991;88:425-534.
134. Nelson H, Szefler SJ, Martin RJ. Regular inhlaed beta adrenergic agonists in the treatment of bronchial asthma: beneficial or detrimental?. American Review of Respiratory Disease 1991;144:249-50.
135. Page C, Costello J. Why Beta agonists should not be used regularly. Respiratory Medicine 1992;86:477-9.
136. Page CP. An explanation of the asthma paradox. American Review of Respiratory Disease 1993;147:S29-S33.
137. Paterson J, Connolly ME, Davies DS, Dollery CT. Isoprenaline resistance and the use of pressurized aerosols in asthma. Lancet 1968;2:426-9.
138. Sears M. Why are deaths from asthma increasing?. European Journal of Respiratory Diseases Supplement 1986;147:175-81.
139. Sears M. Is the routine use of inhaled beta adrenergic agonists appropriate in asthma treatment-No. American Journal of Respiratory & Critical Care Medicine 1995;151:600.
140. Sears M, Rea HH, et al. Asthma mortaility: comparison between new Zealand and England. British medical Journal Clinical Research Edition 1986;293:1342-5.
141. Sly R, Anderson J, Chervinsky P, et al. Adverse effects and complications of treatment with betaadrenergic agonist drugs. Journal of Allergy & Clinical Immunology 1985;75:443-9.
142. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, et al. The use of beta agonists and the risk of death and near death from asthma. New England Journal of Medicine 1992;326:501-6.
143. Suissa S, Ernst P, Bolvin JF. A cohort analysis of excess mortality in asthma and the use of inhaled beta agonists. American Journal of Respiratory and Critical Care Medicine 1994;149:604-10.
144. Taylor DR, Sears MR. Regular versus as-needed inhaled salbutamol in asthma control. Lancet 1994;344:27.
145. Taylor DR, Sears M, Cockcroft DW. The beta-agonist controversy [Review]. Medical Clinics of North America 1996;80:719-48.
146. Van Schayck CP, Cloosterman SGM, Hofland ID, et al. How detrimental is chronic use of bronchodilators in asthma and chronic obstructive pulmonary disease?. American Journal of Respiratory and Critical Care Medicine 1995;151:1317-9.
147. Wanner A. Is the routine use of inhaled beta agonists appropriate in asthma treatment? Yes. American Journal of Respiratory and Critical Care Medicine 1995;151:597-9.
148. Wong CS, Pavord I, Williams J, Britton J, Tattersfield A. Bronchodilator, cardiovascular and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990;336:1396-9.